Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
St Mary's Medical Center
mi
from
San Francisco, CA
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
St Mary's Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
Cancer Center At Blessing Hospital
mi
from
Quincy, IL
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
Cancer Center At Blessing Hospital
mi
from
Quincy, IL
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
Montgomery Cancer Center
mi
from
Mt. Sterling, KY
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
Montgomery Cancer Center
mi
from
Mt. Sterling, KY
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
Meritus Center For Clinical Research
mi
from
Hagerstown, MD
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
Meritus Center For Clinical Research
mi
from
Hagerstown, MD
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
Arena Oncology Associates PC
mi
from
Lake Success, NY
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
Arena Oncology Associates PC
mi
from
Lake Success, NY
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
Carolina BioOncology Institute
mi
from
Huntersville, NC
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
Carolina BioOncology Institute
mi
from
Huntersville, NC
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
William Jennings Bryan Dorn Va Medical Center
mi
from
Columbia, SC
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
William Jennings Bryan Dorn Va Medical Center
mi
from
Columbia, SC
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
South Texas Comprehensive Cancer Centers
mi
from
Corpus Christi, TX
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
South Texas Comprehensive Cancer Centers
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
Southwest Cancer Treatment & Research Center
mi
from
Lubbock, TX
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
Southwest Cancer Treatment & Research Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
Blue Ridge Cancer Care
mi
from
Christiansburg, VA
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
Blue Ridge Cancer Care
mi
from
Christiansburg, VA
Click here to add this to my saved trials
Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers
Randomized Trial of PEITC as a Modifier of NNK Metabolism in Smokers
Status: Enrolling
Updated:  8/29/2012
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers
Randomized Trial of PEITC as a Modifier of NNK Metabolism in Smokers
Status: Enrolling
Updated: 8/29/2012
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Lung Cancer Location: a Repository
Lung Cancer Location: A Prospective Repository
Status: Enrolling
Updated:  9/11/2012
Clarian/IUPUI: University Hospital
mi
from
Indianapolis, IN
Lung Cancer Location: a Repository
Lung Cancer Location: A Prospective Repository
Status: Enrolling
Updated: 9/11/2012
Clarian/IUPUI: University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
GRN1005 for Brain Metastases From Breast or Lung Cancer
A Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  9/13/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
GRN1005 for Brain Metastases From Breast or Lung Cancer
A Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 9/13/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer
A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  9/25/2012
Desert Hematology Oncology Medical Group
mi
from
Rancho Mirage, CA
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer
A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 9/25/2012
Desert Hematology Oncology Medical Group
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer
A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  9/25/2012
Kansas City Cancer Center, LLC
mi
from
Overland Park, KA
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer
A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 9/25/2012
Kansas City Cancer Center, LLC
mi
from
Overland Park, KA
Click here to add this to my saved trials
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer
A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  9/25/2012
Hackensack University Medical Center
mi
from
Hackensack, NJ
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer
A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 9/25/2012
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma
A Pilot Study of 18F FLT PET/CT in Evaluating Early Response to Anti-Proliferative Therapies in Non Small Cell Lung Cancer and Thymic Tumors
Status: Enrolling
Updated:  9/28/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma
A Pilot Study of 18F FLT PET/CT in Evaluating Early Response to Anti-Proliferative Therapies in Non Small Cell Lung Cancer and Thymic Tumors
Status: Enrolling
Updated: 9/28/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study to Test Lung Function After Radiation Therapy
Quantifying Radiation Induced Changes in Pulmonary Function in Irradiated and Non-irradiated Lung Tissue
Status: Enrolling
Updated:  10/23/2012
University of Iowa Department of Radiation Oncology
mi
from
Iowa City, IA
A Study to Test Lung Function After Radiation Therapy
Quantifying Radiation Induced Changes in Pulmonary Function in Irradiated and Non-irradiated Lung Tissue
Status: Enrolling
Updated: 10/23/2012
University of Iowa Department of Radiation Oncology
mi
from
Iowa City, IA
Click here to add this to my saved trials
Stage IIIB/IV Non-Small Cell Lung Cancer
Pazopanib and Weekly Paclitaxel in Stage IIIB/IV Non-small Cell Lung Cancer
Status: Enrolling
Updated:  10/29/2012
Loyola University Medical Center
mi
from
Maywood, IL
Stage IIIB/IV Non-Small Cell Lung Cancer
Pazopanib and Weekly Paclitaxel in Stage IIIB/IV Non-small Cell Lung Cancer
Status: Enrolling
Updated: 10/29/2012
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin
A Phase I Open-Label, Ascending Dose Cohort Study of Gemcitabine Elaidate and Cisplatin in Patients With Advanced Solid Tumors Followed by an Expanded Cohort of Patients With Stage IIIb/IV NSCLC.
Status: Enrolling
Updated:  11/7/2012
Florida Cancer Specialists
mi
from
Fort Myers, FL
A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin
A Phase I Open-Label, Ascending Dose Cohort Study of Gemcitabine Elaidate and Cisplatin in Patients With Advanced Solid Tumors Followed by an Expanded Cohort of Patients With Stage IIIb/IV NSCLC.
Status: Enrolling
Updated: 11/7/2012
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin
A Phase I Open-Label, Ascending Dose Cohort Study of Gemcitabine Elaidate and Cisplatin in Patients With Advanced Solid Tumors Followed by an Expanded Cohort of Patients With Stage IIIb/IV NSCLC.
Status: Enrolling
Updated:  11/7/2012
Tennessee Oncology
mi
from
Nashville, TN
A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin
A Phase I Open-Label, Ascending Dose Cohort Study of Gemcitabine Elaidate and Cisplatin in Patients With Advanced Solid Tumors Followed by an Expanded Cohort of Patients With Stage IIIb/IV NSCLC.
Status: Enrolling
Updated: 11/7/2012
Tennessee Oncology
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Glendale, AZ
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Glendale, AZ
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Anaheim, CA
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Aurora, CO
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Las Vegas, NV
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
New York, NY
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Charleston, SC
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Knoxville, TN
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Austin, TX
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Richmond, VA
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Kennewick, WA
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Kennewick, WA
Click here to add this to my saved trials
Phase 1b Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Phase 1b Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/13/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Phase 1b Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Phase 1b Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/13/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Outcome Measures in Infant/Early Childhood Lung Disease w/ Chest CT Scanning & Lung Function Testing
Differentiating Outcome Measures in Infant and Early Childhood Lung Disease Utilizing Controlled Ventilation Infant/Young Child Chest CT Scanning and Lung Function Testing
Status: Enrolling
Updated:  12/4/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Outcome Measures in Infant/Early Childhood Lung Disease w/ Chest CT Scanning & Lung Function Testing
Differentiating Outcome Measures in Infant and Early Childhood Lung Disease Utilizing Controlled Ventilation Infant/Young Child Chest CT Scanning and Lung Function Testing
Status: Enrolling
Updated: 12/4/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/11/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/11/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/11/2012
Durham VA Medical Center
mi
from
Durham, NC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/11/2012
Durham VA Medical Center
mi
from
Durham, NC
Click here to add this to my saved trials
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/11/2012
Duke Raleigh
mi
from
Raleigh, NC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/11/2012
Duke Raleigh
mi
from
Raleigh, NC
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Mayo Clinic
mi
from
Scottsdale, AZ
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Arizona Cancer Center
mi
from
Tucson, AZ
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
City of Hope
mi
from
Duarte, CA
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
University of Chicago
mi
from
Chicago, IL
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Nevada Cancer Institute
mi
from
Las Vegas, NV
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Nevada Cancer Institute
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Cleveland Clinic
mi
from
Cleveland, OH
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane™ in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/17/2013
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane™ in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/17/2013
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials